[Preliminary study on the value of ratio of serum luteinizing hormone/follicle-stimulating hormone in diagnosis of polycystic ovarian syndrome among women with polycystic ovary].

OBJECTIVE: To investigate the value of ratio of luteinizing hormone (LH) to follicle-stimulating hormone (FSH) in diagnosis of polycystic ovarian syndrome (PCOS) among women with polycystic ovary (PCO) and to compare the difference of the diagnostic criteria between the Rotterdam Consensus and the Committee for Reproductive and Endocrine in Japan Society of Obstetrics and Gynecology. METHODS: By means of transvaginal Doppler ultrasound, 195 women with PCO were diagnosed in Nanfang Hospital of Reproductive Medicine Center and compare difference of multiple clinical indexes according to Rotterdam consensus and Japan consensus respectively. In the mean time, the ratio of LH/FSH, the level of LH, testosterone (T) and recevier operating characteristic (ROC) curve were explored to on the value of diagnosis of PCOS. RESULTS: By Rotterdam consensus, 144 women were diagnosed with PCOS and 51 women were non-PCOS, while 111 were identified as PCOS and 84 were non-PCOS according to Japan consensus. LH/FSH in PCOS and non-PCOS were 1.59 ± 0.84 and 0.85 ± 0.47 respectively when based on Rotterdam consensus, and this ratio were 1.87 ± 0.76 in PCOS and 0.78 ± 0.39 in non-PCOS based on Japan consensus. When using LH/FSH to diagnosis PCOS by Rotterdam consensus and Japan consensus, areas under ROC curve are 0.786 and 0.942, respectively. CONCLUSIONS: The ratio of LH/FSH ≥ 1 provide the significant value in the diagnosis of PCOS. The criteria of the Committee for Reproductive and Endocrine in Japan Society of Obstetrics and Gynecology is more suitable for Chinese patients.

Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma / 中华肿瘤杂志

<p><b>OBJECTIVE</b>To investigate the efficacy of the combination of gemcitabine with capecitabine in the chemotherapy for patients with relapsed or metastatic biliary tract carcinoma.</p><p><b>METHODS</b>Forty-one patients with unresectable relapsed or metastatic carcinoma of the biliary tract were treated from March 2000 to December 2004. The regimen consisted of intravenous administration of gemcitabine plus oral intake of capecitabine every 3 weeks for more than 2 cycles. The parameters including tumor response, clinical benefit rate,survival and safety were observed.</p><p><b>RESULTS</b>Thirty-six patients were valuable and 5 patients were excluded from this series due to various reasons. Eleven patients (30.1%) had a partial response and another 11 patients (30.1%) experieced stable disease with a clinical benefit rates of 61.1%. The median overall survival time and time to progression were 10 months and 6 months, respectively. The one-year survival rate was 40.0%. The adverse events including nausea, diarrhea and hand-foot syndrome, fatigue, neutropenia, thrombocytopenia were frequently observed, which were usually in grade I or II, rarely in grade III and none in grade IV (NCI-CTC).</p><p><b>CONCLUSION</b>Our results show that the regimen of gemcitabine combined with capecitabine is effective and well tolerated in patients with unresectable relapsed or metastatic carcinoma of the biliary tract.</p>

Relapse or disease-free survival rate prediction value of TIP30 protein expression in NSCLC / 中国癌症杂志

Background and Purpose:TIP30 is a newly found tumor suppressing protein that has low level expression in many kinds of tumor cell lines,and it inhibits the growth of tumor cells of different origin.In this article,we want to probe into the value of a newly found tumor suppressor gene TIP30 as a molecular marker for the prediction of relapse or metastasis of lung cancer patients.Methods:In our present study,immunohistochemical analyses of a retrospective database of pathologic specimens were used to demonstrate the expression of TIP30 protein in NSCLC.Results:The low expression of TIP30 protein in NSCLC tumor tissue was statistically significant in the clinical stage,relapse or metastasis or 5 year disease-free survival rate,whereas low levels of TIP30 expression did not relate to histologic type and histologic differentiation.Conclusions:TIP30 protein may be used as a molecular marker to identify and predict the relapse or metastasis of NSCLC,and may provide a new clue for the clinical doctor to evaluate the prognosis of patients with NSCLC.